| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| UNITED STATES | Region | 2025 | USD | 20,876.0 | 70.9% |
| Europe | Region | 2025 | USD | 5,064.0 | 17.2% |
| Other International | Region | 2025 | USD | 3,503.0 | 11.9% |
| UNITED STATES | Region | 2024 | USD | 20,591.0 | 71.6% |
| Europe | Region | 2024 | USD | 4,634.0 | 16.1% |
| Other International | Region | 2024 | USD | 3,529.0 | 12.3% |
| UNITED STATES | Region | 2023 | USD | 19,438.0 | 71.7% |
| Europe | Region | 2023 | USD | 4,310.0 | 15.9% |
| Other International | Region | 2023 | USD | 3,368.0 | 12.4% |
| UNITED STATES | Region | 2022 | USD | 18,884.0 | 69.2% |
| Europe | Region | 2022 | USD | 4,469.0 | 16.4% |
| Other International | Region | 2022 | USD | 3,928.0 | 14.4% |
| UNITED STATES | Region | 2021 | USD | 19,267.0 | 70.6% |
| Europe | Region | 2021 | USD | 4,874.0 | 17.9% |
| Other International | Region | 2021 | USD | 3,164.0 | 11.6% |
| UNITED STATES | Region | 2020 | USD | 18,217.0 | 73.8% |
| Europe | Region | 2020 | USD | 4,135.0 | 16.8% |
| Other International | Region | 2020 | USD | 2,337.0 | 9.5% |
| Products, Other HIV | Product | 2025 | USD | 20,752.0 | 79.7% |
| Cell Therapy Products, Total Cell Therapy Product Sales | Product | 2025 | USD | 2,183.0 | 8.4% |
| Trodelvy | Product | 2025 | USD | 1,397.0 | 5.4% |
| Veklury | Product | 2025 | USD | 911.0 | 3.5% |
| Other Products, Total Other product sales | Product | 2025 | USD | 799.0 | 3.1% |
| Products, Other HIV | Product | 2024 | USD | 19,612.0 | 75.5% |
| Cell Therapy Products, Total Cell Therapy Product Sales | Product | 2024 | USD | 2,376.0 | 9.1% |
| Veklury | Product | 2024 | USD | 1,799.0 | 6.9% |
| Trodelvy | Product | 2024 | USD | 1,315.0 | 5.1% |
| Other Products, Total Other product sales | Product | 2024 | USD | 889.0 | 3.4% |
| Products, Other HIV | Product | 2023 | USD | 18,231.0 | 71.2% |
| Cell Therapy Products, Total Cell Therapy Product Sales | Product | 2023 | USD | 2,239.0 | 8.8% |
| Veklury | Product | 2023 | USD | 2,184.0 | 8.5% |
| Trodelvy | Product | 2023 | USD | 1,063.0 | 4.2% |
| Hepatitis B Virus / Hepatitis Delta Virus Product | Product | 2023 | USD | 1,017.0 | 4.0% |
| Other Products, Total Other product sales | Product | 2023 | USD | 859.0 | 3.4% |
| Products, Other HIV | Product | 2022 | USD | 17,251.0 | 67.6% |
| Veklury | Product | 2022 | USD | 3,905.0 | 15.3% |
| Cell Therapy Products, Total Cell Therapy Product Sales | Product | 2022 | USD | 1,758.0 | 6.9% |
| Hepatitis B Virus / Hepatitis Delta Virus Product | Product | 2022 | USD | 988.0 | 3.9% |
| Other Products, Total Other product sales | Product | 2022 | USD | 946.0 | 3.7% |
| Trodelvy | Product | 2022 | USD | 680.0 | 2.7% |
| Products, Other HIV | Product | 2021 | USD | 16,365.0 | 64.6% |
| Veklury | Product | 2021 | USD | 5,565.0 | 22.0% |
| Cell Therapy Products, Total Cell Therapy Product Sales | Product | 2021 | USD | 1,047.0 | 4.1% |
| Other Products, Total Other product sales | Product | 2021 | USD | 1,027.0 | 4.1% |
| Hepatitis B Virus / Hepatitis Delta Virus Product | Product | 2021 | USD | 969.0 | 3.8% |
| Trodelvy | Product | 2021 | USD | 380.0 | 1.5% |
| Products, Other HIV | Product | 2020 | USD | 16,996.0 | 87.2% |
| Other Products, Total Other product sales | Product | 2020 | USD | 1,886.0 | 9.7% |
| Cell Therapy Products, Total Cell Therapy Product Sales | Product | 2020 | USD | 607.0 | 3.1% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
